Medical Technology Pharmaceuticals Regulations 
Bill Of Health
SEPTEMBER 20, 2022
New mRNA vaccines, underpinned by decades of public investment , had been authorized by global regulators. Dose shortages elevated the role of pharmaceutical executives. Pharmaceutical corporations hoarded technology that could have helped alleviate scarcity. Private decisions did not match public health need.
Healthcare ECONOMIST
DECEMBER 28, 2022
In the context of this fast-moving political debate, FTI Consulting supported INTERPAT, a non-profit biopharmaceutical consortium, and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) in developing a White Paper and peer-reviewed article on the role of IP in the biopharmaceutical sector.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bill Of Health
SEPTEMBER 22, 2022
After graduating from law school, she has trained at Hogan Lovells in their Milan office, specializing in pharmaceutical patent litigation. She has previously published articles on synthetic biology regulation and governance, end stage renal disease payment reform, and comparative analyses of learning disorder policy. Louis (USA).
Bill Of Health
MARCH 23, 2023
By Enrique Santamaría Together with the Data Governance Act (DGA) and the General Data Protection Regulation (GDPR), the proposal for a Regulation on the European Health Data Space (EHDS) will most likely form the new regulatory and governance framework for the use of health data in the European Union. health data). If so, how?
HIT Consultant
AUGUST 18, 2021
In view of this, regulators have demonstrated unprecedented flexibility and collaboration with key industry players to support the delivery of treatments to the market. First, regulators liberally issued Emergency Use Authorizations (EUAs) for COVID-19 products to expedite the testing, treatment, and vaccination of patients.
Bill Of Health
NOVEMBER 7, 2023
From national disparities across populations, to global inequalities in access, to scarce medical technologies, from ventilators to vaccines, inequalities have been an overriding feature of this pandemic. Deep inequities and discrimination were manifested across the board.
Bill Of Health
SEPTEMBER 16, 2024
She is interested in mass torts, drug product liability, pharmaceutical antitrust, and the administrative law that affects health-related regulations promulgated by agencies. 2026) research interests include innovative medical technologies and chronic disease policy. Rebekah Ninan’s (J.D. Rupa Palanki’s (J.D.
Expert insights. Personalized for you.
98 
Let's personalize your content